Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
Carlos Doti, VP US Medical Affairs Oncology at AstraZeneca, shared on LinkedIn:
”As I reflect on another ASH, I’m reminded why this meeting is such a powerful close to the year – where science, collaboration and patient experiences come together to shape the future of hematology.
This year, I participated in two meaningful AstraZeneca events:
Moderating our annual Patient Advocacy Exchange panel with advocacy leaders focused on shared decision-making and patient navigation, discussing how to break down barriers and promote equitable access to care.
Hosting our first-ever AZHemeTalks – a live, pop-up series – at our booth, where I spoke with a clinical trial patient and her doctor about how treatment choices impact daily life.
The video here shows how we brought this activation to life through 4 expert panels focused on the treatment landscape in leukemia, lymphomas and multiple myeloma.”
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation
-
Aug 22, 2026, 07:35Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study